Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

723
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
723
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.1K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.1K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

397
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
397
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

561
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
561

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current progress and obstacles for automated classification of causes of death based on death certificates: A systematic review.

International journal of medical informatics·2026
Same author

Population-level cardiovascular risk prediction models including biochemical predictors in 800 000 individuals.

European heart journal open·2026
Same author

New Zealand Electronic Health Data for Cardiovascular Research: A Review.

Clinical epidemiology·2026
Same author

A transformer-based survival model for prediction of all-cause mortality in patients with heart failure: a multi-cohort study.

NPJ digital medicine·2026
Same author

Half a century of declining acute coronary syndrome incidence is ending and ethnic inequity is rising: ANZACS-QI 88.

The New Zealand medical journal·2025
Same author

Long-Term Clinical Outcomes and Predictors of Mortality in Implantable Cardioverter-Defibrillator Recipients in New Zealand (ANZACS-QI 83).

Heart, lung & circulation·2025

Related Experiment Video

Updated: Apr 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Lifetime risk: does it help to decide who gets statins and when?

Rod Jackson1

  • 1School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Current Opinion in Lipidology
|July 1, 2014
PubMed
Summary

Short-term cardiovascular disease risk effectively guides statin treatment decisions. Lifetime risk assessment is less useful, but a risk trajectory approach may improve personalized cardiovascular disease prevention strategies.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Related Experiment Videos

Last Updated: Apr 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Health Policy

Background:

  • Current guidelines emphasize cardiovascular disease (CVD) risk over LDL-cholesterol for lipid-lowering treatment.
  • Debate exists on whether to use short-term versus lifetime CVD risk predictions for treatment decisions.

Purpose of the Study:

  • To evaluate if predicted lifetime cardiovascular disease (CVD) risk, alongside short-term risk, should inform statin prescribing.
  • To determine the optimal approach for identifying individuals who benefit most from statin therapy.

Main Methods:

  • Review of meta-analyses on statin trial outcomes.
  • Analysis of studies reporting lifetime and alternative CVD risk prediction models.
  • Evaluation of the utility of different risk prediction horizons.

Main Results:

  • Statin's CVD risk reduction is proportional to pretreatment short-term CVD risk.
  • Most adults are classified as high lifetime CVD risk, diminishing its utility for guiding treatment.
  • A novel risk trajectory model shows promise for improved risk assessment.

Conclusions:

  • Short-term CVD risk is crucial for guiding timely statin therapy.
  • Lifetime CVD risk alone is not sufficiently discriminatory for personalized treatment.
  • A lifetime risk trajectory approach may enhance the identification of individuals benefiting from statins.